Rainer Rupprecht Selected Research

N- benzyl- N- ethyl- 2- (7,8- dihydro- 7- methyl- 8- oxo- 2- phenyl- 9H- purin- 9- yl)acetamide

2/2019	The agonistic TSPO ligand XBD173 attenuates the glial response thereby protecting inner retinal neurons in a murine model of retinal ischemia.
7/2009	Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rainer Rupprecht Research Topics

Disease

16	Panic Disorder (Panic Attack) 10/2014 - 01/2002
15	Anxiety Disorders (Anxiety Disorder) 03/2022 - 01/2002
13	Major Depressive Disorder (Major Depressive Disorders) 03/2022 - 06/2005
12	Tinnitus 01/2019 - 01/2012
10	Mood Disorders (Mood Disorder) 01/2017 - 03/2002
9	Neuroinflammatory Diseases 06/2022 - 01/2014
9	Sleep Deprivation 03/2016 - 05/2002
7	Neoplasms (Cancer) 12/2021 - 12/2005
7	Schizophrenia (Dementia Praecox) 05/2019 - 08/2004
6	Mental Disorders (Mental Disorder) 03/2022 - 01/2010
6	Depressive Disorder (Melancholia) 05/2019 - 04/2004
5	Bipolar Disorder (Manic Depressive Psychosis) 05/2019 - 07/2003
4	Glioma (Gliomas) 12/2021 - 01/2012
4	Inflammation (Inflammations) 01/2020 - 01/2014
3	Gliosis 02/2019 - 12/2010
2	Postpartum Depression (Post-Natal Depression) 03/2022 - 01/2022
2	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2022 - 01/2019
2	Disease Progression 01/2021 - 03/2003
2	Infections 05/2019 - 01/2017
2	Multiple Sclerosis 10/2017 - 03/2010
2	Sleepiness 01/2017 - 03/2016
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2012 - 07/2009
2	Substance-Related Disorders (Drug Abuse) 01/2010 - 01/2008
2	Treatment-Resistant Depressive Disorder 01/2007 - 01/2006
1	Progressive Multifocal Leukoencephalopathy 06/2022
1	Acute Pain 05/2022
1	Cognitive Dysfunction 01/2022
1	Corticobasal Degeneration 01/2021
1	Necrosis 01/2021
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2021
1	Tauopathies 01/2021
1	Ischemia 02/2019
1	Cardiovascular Diseases (Cardiovascular Disease) 12/2018
1	Glioblastoma (Glioblastoma Multiforme) 07/2018
1	Relapsing-Remitting Multiple Sclerosis 10/2017
1	Fatigue 01/2017
1	Pain (Aches) 01/2017
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2016
1	Neuralgia (Stump Neuralgia) 01/2016

Drug/Important Bio-Agent (IBA)

18	NeurosteroidsIBA 03/2022 - 01/2002
16	Antidepressive Agents (Antidepressants)IBA 01/2017 - 03/2003
15	Proteins (Proteins, Gene)FDA Link 03/2022 - 07/2003
10	LigandsIBA 03/2022 - 07/2009
8	Pharmaceutical PreparationsIBA 06/2014 - 05/2002
7	gamma-Aminobutyric Acid (GABA)IBA 03/2022 - 01/2002
7	Anti-Anxiety Agents (Anxiolytics)IBA 01/2012 - 01/2003
7	TetragastrinIBA 01/2011 - 02/2003
6	GABA-A Receptors (GABA(A) Receptor)IBA 11/2012 - 01/2002
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 12/2010
5	Antipsychotic Agents (Antipsychotics)IBA 06/2014 - 11/2005
4	Amino Acids FDA Link 06/2022 - 07/2003
4	BenzodiazepinesIBA 01/2022 - 05/2005
4	Biological ProductsIBA 12/2018 - 01/2006
3	Pregnanolone (Allopregnanolone)IBA 03/2022 - 02/2014
3	CytokinesIBA 01/2021 - 05/2019
3	Quetiapine Fumarate (Seroquel)FDA Link 06/2014 - 01/2012
3	Mirtazapine (Rexer)FDA LinkGeneric 01/2009 - 03/2003
3	Sodium Lactate FDA LinkGeneric 01/2006 - 02/2003
2	brexanoloneIBA 03/2022 - 01/2022
2	zuranoloneIBA 03/2022 - 01/2022
2	Interleukin-6 (Interleukin 6)IBA 01/2020 - 05/2019
2	ChemokinesIBA 05/2019 - 01/2017
2	Retinaldehyde (Retinal)IBA 02/2019 - 01/2014
2	N- benzyl- N- ethyl- 2- (7,8- dihydro- 7- methyl- 8- oxo- 2- phenyl- 9H- purin- 9- yl)acetamideIBA 02/2019 - 07/2009
2	Hypnotics and Sedatives (Sedatives)IBA 01/2019 - 01/2012
2	Butyric Acid (Butanoic Acid)IBA 11/2009 - 04/2004
2	Serotonin (5 Hydroxytryptamine)IBA 01/2009 - 11/2005
2	GTP-Binding Proteins (G-Protein)IBA 07/2002 - 03/2002
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 06/2022
1	Glucose (Dextrose)FDA LinkGeneric 06/2022
1	Opioid Analgesics (Opioids)IBA 05/2022
1	Immunologic Factors (Immunomodulators)IBA 03/2022
1	Diazepam (Valium)FDA LinkGeneric 01/2022
1	InterleukinsIBA 01/2021
1	Interleukin-7 (Interleukin 7)IBA 01/2021
1	Interleukin-12 (IL 12)IBA 01/2021
1	Interleukin-15 (Interleukin 15)IBA 01/2021
1	Interleukin-16 (Interleukin 16)IBA 01/2021
1	Interleukin-17 (Interleukin 17)IBA 01/2021
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	CC ChemokinesIBA 01/2020
1	Interleukin-1beta (Interleukin 1 beta)IBA 05/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2019
1	C-Reactive ProteinIBA 05/2019
1	salicylhydroxamic acid (SHAM)IBA 01/2018
1	tacrolimus binding protein 5IBA 03/2017
1	Hormones (Hormone)IBA 03/2017
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 03/2017
1	Adrenocorticotropic Hormone (ACTH)FDA Link 03/2017
1	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 03/2017
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2017
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2017
1	Wakefulness-Promoting AgentsIBA 01/2017
1	Indicators and Reagents (Reagents)IBA 03/2016
1	Desipramine (Pertofrane)FDA LinkGeneric 01/2016

Therapy/Procedure

14	Transcranial Magnetic Stimulation 01/2018 - 05/2002
7	Therapeutics 05/2021 - 01/2007
5	Drug Therapy (Chemotherapy) 01/2017 - 01/2006
2	Transcranial Direct Current Stimulation 01/2019 - 12/2017
2	Combined Modality Therapy 07/2018 - 01/2018